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Abstract
Introduction: Pegvisomant-related lipohypertrophy may revert when changing the site of injection, but the
lipohypertrophy may recur at the new site of injection. The strength of evidence, however, is weak and comes
from information obtained from physical examination only.
Case presentation: We studied two Caucasian women with acromegaly, aged 51 and 71 years, with pegvisomant-
related lipohypertrophy. Our two patients were evaluated at baseline, when the site of pegvisomant injection was
the periumbilical abdominal region, and then four months after switching the injection site from the abdomen to
both thighs. Both physical examination and radiological studies (magnetic resonance imaging and dual energy X-
ray absorptiometry) demonstrated that the abdominal lipohypertrophy progressively reverted in both patients after
switching the site of injection to the thighs. However, lipohypertrophy reappeared at the new site of injection. The
radiological outcome confirmed the reversibility of pegvisomant-related lipohypertrophy and strengthened the
body of evidence on this issue.
Conclusion: In clinical practice, physical examination of the injection site or sites leads to an early detection of
lipohypertrophy during pegvisomant treatment. Radiological procedures may be of help to confirm subcutaneous
fat changes and for a precise monitoring of fat redistribution. Patients should get appropriate information about
lipohypertrophy before starting pegvisomant treatment since the rotation of the site of injection may prevent
lipohypertrophy.
Introduction
The growth hormone (GH) receptor antagonist pegviso-
mant is effective in the control of acromegaly since it
decreases serum insulin-like growth factor 1 (IGF-1)
and improves the health status of people with acrome-
galy [1]. In clinical practice, clinicians recommend peg-
visomant for recurrences of acromegaly after
transsphenoidal surgery, especially when the primary
medical treatment with somatostatin analogues (SSA) is
ineffective [1]. Pegvisomant treatment is well tolerated
and is considered safe [1] even if we consider long-term
studies [1-3]. Clinically relevant side effects include a
transient increase of liver enzymes [1,4], an increase in
size of the pituitary tumor [1-6] and headache [2]; their
frequency is similar to that of other treatment regimens
[6]. In 2006, Maffei et al. first described a condition of
lipohypertrophy at the site of pegvisomant injection in
two people with acromegaly [7]. Subsequently, further
case series [8,9] and retrospective cross-sectional ana-
lyses of larger cohorts of patients treated with pegviso-
mant [2,3] supplied similar observations. However, the
actual pathogenetic mechanism involved in pegviso-
mant-related lipohypertrophy remains unknown. Both
GH-deficiency and the local modulation of lipolytic
enzymes, such as 11-b-hydroxysteroid dehydrogenase,
may be involved in the development of pegvisomant-
related lipohypertrophy [7-9]. In the clinic, pegvisomant
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withdrawal seems to reverse subcutaneous fat accumula-
tion; however, evidence provided until now has come
from observations of a single case report, patients’ pic-
tures of the site of fat accumulation [8] and the observa-
tion of body changes recorded at physical examination
[9]. An evidence-based outcome of lipohypertrophy
reversion is lacking since a radiological evaluation before
and after switching the site of injection is not yet avail-
able in literature [7-9], leaving the strength of the evi-
dence weak at the moment. Notwithstanding the
weakness of evidence, however, experts provided some
simple clinical recommendations [9].
We document the reversibility of pegvisomant-related
lipohypertrophy by a prospective radiological evaluation,
thus improving the strength of evidence for this clinical
condition.
Cases presentation
Patient 1 is a 51-year-old Caucasian woman with acro-
megaly, treated with pegvisomant (Somavert, Pfizer, NY,
USA) after three unsuccessful transsphenoidal endo-
scopic tumor resections and ineffective somatostatin
analog treatment. This patient presented to the outpati-
ent clinic of Endocrinology of Modena with the clinical
suspicion of acromegaly. A hormonal analysis demon-
strated raised serum levels of IGF-1 (666 ng/mL; normal
range: 94 ng/mL to 267 ng/mL) and basal GH (22.1 ng/
mL) and a pituitary magnetic resonance imaging (MRI)
scan disclosed a pituitary macroadenoma with a dia-
meter of 12 mm, which extended to her right cavernous
sinus. Our patient underwent three transsphenoidal
endoscopic pituitary tumor resections, which did not
lead to complete tumor resection because of residual tis-
sue within the right cavernous sinus. She was treated
with the somatostatin analog, octreotide long-acting
release (LAR) (Sandostatin LAR, Novartis Pharma AG,
Basel, Switzerland), at the dosage of 20 mg intramuscu-
larly every 28 days for three months followed by 30 mg
every 20 days but this did not lower her IGF-1 serum
levels (821.3 ng/dL and 741.3 ng/mL, respectively).
Thus, she was started on pegvisomant treatment 13
months after the initial diagnosis of acromegaly, at a
dosage of 10 mg/day delivered subcutaneously, which
rapidly decreased her IGF-1 serum level (251.3 ng/mL
after two months of treatment). In July 2008, our patient
underwent pituitary-directed Gamma-Knife stereotaxic
radiosurgery. She is still under pegvisomant treatment at
a dosage of 10 mg subcutaneously, daily resulting in a
good control of her serum IGF-1 (206 ng/mL).
Patient 2 is a 71-year-old Caucasian woman with acro-
megaly, treated with surgery 23 years before the initia-
tion of pegvisomant treatment; the latter was
administered because all previous pharmacological treat-
ments failed. This patient came to our attention with
IGF-1 serum levels higher than normal (280.1 ng/mL;
normal range: 20 ng/mL to 182 ng/mL) during cabergo-
line treatment (Dostinex, Pfizer) at a dose of 0.1 mg
twice weekly. Our patient reported a previous long his-
tory of acromegaly treated with surgery by means of a
conventional transnasal transsphenoidal approach. A
pituitary MRI showed a small piece of residual adeno-
matous tissue. Previous pharmacological treatments
included bromocriptine, octreotide (Sandostatin, Novar-
tis Pharma AG), octreotide LAR, and lanreotide (Ipstyl,
Ipsen, Milan, Italy) but our patient had discontinued
somatostatin and SSAs due to intolerance to the drugs;
notwithstanding, they were effective in controlling the
disease. As the control of the disease was suboptimal
(her serum IGF-1 was constantly higher than the upper
limit of the normal range) with cabergoline treatment,
our patient was switched to pegvisomant therapy at a
dose of 10 mg/day subcutaneously. The latter was effec-
tive in normalizing her IGF-1 serum levels (150 ng/mL
after two months of treatment).
After starting pegvisomant therapy, both women
developed a rapid, progressive increase in subcutaneous
fat depots at the site of injection in the abdominal peri-
umbilical region. Both patients reported abdominal fat
accumulation, and physical examinations performed
four and two months after starting pegvisomant treat-
ment for patient 1 and patient 2, respectively, revealed a
soft, painless anterior abdominal wall swelling, consist-
ing with a thickening of subcutaneous fat tissue.
Both patients underwent detailed clinical and radiolo-
gical investigations at baseline (Phase 1), after at least
eight months of pegvisomant treatment (10 mg once a
day) at the abdominal site, when abdominal lipohyper-
trophy had just started developing. Soon after the base-
line evaluation, both patients switched the injection site
from the abdomen to the anterior surface of both
thighs. The dose of pegvisomant was not changed. A
radiological evaluation was repeated after four months
(Phase 2). A hormonal evaluation and study of their
body composition by means of a physical evaluation,
MRI of the abdomen and thighs and dual energy X-ray
absorptiometry (DXA), were performed in Phase 1 and
Phase 2 with the aim of detecting and quantifying
changes in their subcutaneous adipose tissue.
At physical examination, the abdominal wall swelling
decreased progressively in both patients after switching
the site of injection to the thighs. Swelling, however,
developed at these new sites of pegvisomant injection in
both patients within four months.
The MRI images and evaluation of fat mass content
with DXA (Table 1) confirmed a reduction in abdominal
subcutaneous fat thickness in patient 1 (Figure 1) and
patient 2 (Figure 2), together with a concomitant
increase in the subcutaneous fat at the anterior surface
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of both thighs in patient 1 (Figure 3) and patient 2 (Fig-
ure 4). Body fat thickness also increased in the flanks
and back areas (only in patient 2; Figure 2) and the pos-
terior surface of the thighs in both patients (Figures 3
and 4).
A tendency for a reduction in IGF-1 and IGF-binding
protein 3 and a better control of the disease was docu-
mented, especially in patient 2 (Table 1). Neither patient
experienced other side effects; in particular, no enlarge-
ment of the pituitary residual tumor was recorded. Not-
withstanding advice by us about the benefits of the
Table 1 Hormonal and adipose tissue measurements by DXA in the two women with acromegaly.
Parameters Normal range Patient Phase 1a Phase 2b
Serum IGF-1 (ng/mL) 94 to 267
(60.8 to 297.7)c
Patient 1 264 252
20 to 182
(34.5 to 219)c
Patient 2 162.0 94
Serum IGFBP-3 (ng/mL) 3400 to 6900 Patient 1 5670 5550
Patient 2 4737 3623
Body weight (kg) - Patient 1 79.0 81.5
Patient 2 58.3 59.5
Abdominal fat on DXA (g) - Patient 1 11555 10033
Patient 2 14200 13133
Percentage of abdominal fat on DXA (%) - Patient 1 32.3 31.6
Patient 2 43.9 43.1
Thigh fat on DXA (g) - Patient 1 8344 9032
Patient 2 7883 9692
Percentage of thigh fat on DXA (%) - Patient 1 32 33
Patient 2 43.7 47.5
Total body fat on DEXA (g) - Patient 1 25285 27450
Patient 2 27321 29212
Percentage of total body fat on DEXA (%) - Patient 1 34.7 36.9
Patient 2 44.4 46.8
Total fat free mass on DEXA (g) - Patient 1 47590 47000
Patient 2 34190 33149
Percentage of total fat free mass on DEXA (%) - Patient 1 65.3 63.1
Patient 2 55.6 53.2
aPegvisomant (10 mg/day) administered by subcutaneous injection into the abdomen; bpegvisomant (10 mg/day) administered by subcutaneous injection into
the thighs; cage-related ranges from the Laboratory of Modena and the Italian population.
Figure 1 Abdominal MRI scans of patient 1 when injecting pegvisomant (10 mg/day) subcutaneously in her abdomen (Phase 1) and
thighs (Phase 2).
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treatment and the importance of continuing pegviso-
mant administration, patient 2 decided to stop pegviso-
mant because of the discomfort related to
lipohypertrophy. In patient 2, pegvisomant withdrawal
resulted in a progressive disappearance of the lipohyper-
trophy. Patient 1 was asked to rotate the site of injection
over several districts (thighs, abdomen, arms and but-
tocks). As a consequence, a minimal swelling developed
at these sites, without affecting self-image and patient’s
compliance to the treatment.
Discussion
The clinical observation of pegvisomant-related lipohy-
pertrophy is recent and has been documented in a small
number of cases [7,8]. In 2008, the group of Melmed
based their extensive clinical experience on the descrip-
tion of seven cases. The physical examination of these
patients suggested that pegvisomant-related lipohyper-
trophy may be reversible [9], as previously suggested [8],
but that it may develop again at the new site of injection
[9]. The latter study is the largest in terms of the num-
ber of patients enrolled, but it does not provide objec-
tive evidence of pegvisomant-related lipohypertrophy
reversibility because of the lack of radiological out-
comes. The two cases described here strengthen the evi-
dence on pegvisomant-related lipohypertrophy
reversibility as well as on its possible recurrence at the
new site of injection. In fact, subcutaneous fat changes
documented with MRI provide a highly powerful out-
come, thus confirming and reinforcing the knowledge
on this clinical condition associated with subcutaneous
pegvisomant injection [7-9]. Of note, the occurrence of
lipohypertrophy has been observed in 10 women with
acromegaly, of the total 12 cases described in detail
until now (including the two cases here described) [7-9].
From this cases review, it seems that the risk of develop-
ing pegvisomant-related lipohypertrophy is higher in
women than in men [9]. Body image changes are of
concern, especially in women. This issue is of clinical
relevance since, even though lipohypertrophy is not
Figure 2 Abdominal MRI scans of patient 2 when injecting pegvisomant (10 mg/day) subcutaneously in her abdomen (Phase 1) and
thighs (Phase 2).
Figure 3 MRI scans of the thighs of patient 1 when injecting pegvisomant (10 mg/day) subcutaneously in her abdomen (Phase 1) and
thighs (Phase 2).
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considered a serious adverse event [2-4], it may compro-
mise the patient’s compliance to treatment by altering
self-image [4,9], as confirmed also by this report. The
results from MRI evaluation show that lipohypertrophy
of the thighs seems to be quantitatively smaller than
that previously developed at the abdomen, probably as a
consequence of the shorter period of pegvisomant injec-
tion at the thigh sites. Accordingly, the reduction of
lipohypertrophy seems to be associated with a better
control of IGF-1 serum levels in both patients, especially
patient 2 (Table 1). The better control of IGF-1 serum
levels occurring during phase 2 in both subjects is
further substantiated by the corresponding increase in
body weight and total body fat mass as well as by the
decrease in total body fat free mass (Table 1). Further-
more, fat redistribution at both the abdominal (Figures
1 and 2) and thighs (Figures 3 and 4), particularly the
increase in body fat in the posterior areas of the abdo-
men and the thighs, during Phase 2 proves a better con-
trol of the disease. As suggested by Marazuela et al. [8],
increased subcutaneous fat at the site of injection may
negatively affect pegvisomant absorption. With this in
mind, whether or not reducing the frequency of pegviso-
mant injection [10] or changing the dosage may be suc-
cessful in preventing lipohypertrophy and ensuring a
concomitant good control of the disease requires further
elucidation.
Conclusion
Pegvisomant-related lipohypertrophy develops at the site
of injection and it may be reversible, but it could also
reappear at the new site of injection. According to the
results provided by us and other authors [7-9], practical
clinical advice for patients, useful for avoiding the wor-
sening of patient’s compliance to treatment, should
include appropriate information about the possible
occurrence of lipohypertrophy at the injection site and
its reversibility, the requirement to rotate the injection
site frequently and self-monitoring of changes at the site
of injection. Furthermore, the clinical follow-up of the
person with acromegaly under pegvisomant treatment
should also include physical examination of the injection
site or sites for the early detection of lipohypertrophy
[9], which might also be performed using radiological
procedures (such as ultrasound or MRI), which are use-
ful for monitoring changes in subcutaneous fat.
Consent
Written informed consent for publication of this case
series and any accompanying images was obtained from
the patients. Copies of the written consent are available
for review by the Editor-in-Chief of this journal.
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